<< Back
Jul 16, 2018

Tandem Diabetes Care Schedules Second Quarter 2018 Earnings Press Release and Conference Call

SAN DIEGO--(BUSINESS WIRE)--Jul. 16, 2018-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its second quarter 2018 results after the financial markets close on Monday, July 30, 2018. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its second quarter 2018 financial and operating results.

Conference Call/Webcast Details:
Date: July 30, 2018
Time:4:30pm Eastern Time (1:30pm Pacific Time)
Toll Free Dial-In Number: (855) 427-4396
International Dial-In Number: (484) 756-4261
Conference ID: 7975966
Webcast Link: https://edge.media-server.com/m6/p/9tbna22o

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2™ Insulin Pump with Basal-IQ™ technology. The t:slim X2 Pump is capable of remote feature updates using a personal computer and is the only automated insulin delivery device approved for children as young as 6 years old. Tandem is based in San Diego, California.

Tandem Diabetes Care is a registered trademark, and t:slim X2 and Basal-IQ are trademarks of Tandem Diabetes Care, Inc.

Source: Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.
Media Contact:
Steve Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor Contact:
Susan Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com